CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Eligible age
18+ yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Sponsor: VA Office of Research and Development
You may qualify if…
- ✓ On hemodialysis
- ✓ Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol
You may not qualify if…
- ✕ Impaired decision-making capacity
- ✕ Patients not receiving carvedilol who have a history of asthma
- ✕ known hypersensitivity to any component of either drug
- ✕ Provider unwilling to sign a new medication order for a randomized patient
- ✕ No surrogate consent will be allowed
Where it's recruiting
Long Beach
Aurora
West Haven
Gainesville
Decatur
Chicago
Iowa City
Boston
Minneapolis
Omaha
Albuquerque
Durham · Salisbury
Source: ClinicalTrials.gov · NCT05931276 · last updated 2026-10-13